Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to evaluate durability of effectiveness (beyond one year) of the Alair System in patients with severe persistent asthma. The study will consist of Alair-group subjects who are currently in the follow-up phase (out to 5 years) of the AIR2 Trial (Protocol #04-02, clinicaltrials.gov number NCT00231114).
Durability of the treatment effect will be evaluated by comparing the proportion of subjects who experience severe exacerbations during the first year after Alair treatment with the proportion of subjects who experience severe exacerbations during subsequent 12 month periods out to 5 years.
All Alair group subjects in the AIR2 Trial are being followed out to 5 years as per the AIR2 Trial protocol. The data that are to be used to determine durability of effectiveness as described in the present protocol (Protocol #10-01) are being collected under the existing AIR2 Trial protocol (Protocol # 04-02).
Study Hypothesis: An empirical demonstration of the durability of the treatment effect will be used to show that the proportion of subjects experiencing severe exacerbations for the first year compared with the proportions of subjects experiencing severe exacerbations in subsequent years do not get substantially worse.
The primary statistical objective is to demonstrate that the proportion of subjects who experience severe exacerbations in the subsequent 12-month follow-up (for Year 2, Year 3, Year 4 and Year 5 [in 12-month periods]) is not statistically worse when compared with the proportion of first 12-months, which begins 6-weeks after the last Alair treatment. This objective will be met if the upper 95% confidence limit of the difference in proportions (i.e., the subsequent 12-month proportion minus the first 12-month proportion) is less than 20%.
This will be an open-label, single arm study designed to demonstrate the durability of effectiveness (beyond one year) of the Alair System in patients with severe persistent asthma.
Durability of treatment effect will be evaluated by comparison of the proportion of subjects experiencing severe exacerbations during the first year after the Alair treatment to subsequent 12-month periods out to 5 years.
The 12-month periods will begin 6 weeks post-last Alair bronchoscopy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Alair Group | Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02, NCT00231114) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bronchial Thermoplasty with the Alair System | Device | Bronchial Thermoplasty with the Alair System |
|
| Measure | Description | Time Frame |
|---|---|---|
| Severe Exacerbations | The primary endpoint will be the proportion of subjects experiencing severe exacerbations during the first year after the Alair treatment compared to subsequent 12-month periods out to 5 years. This objective will be met if the upper 95% confidence limit of the difference in proportions (i.e., the subsequent 12-month proportion minus the first 12-month proportion) is less than 20%. Severe exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02). | 12 month periods out to 5 Years |
| Measure | Description | Time Frame |
|---|---|---|
| Severe Exacerbations | Number of severe exacerbations per subject per year. Severe exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
All Alair group subjects who have participated in the AIR2 Trial (NCT00231114) and were not lost to follow-up at the end of the 12 month premarket visit, and those who are willing to comply with the study protocol and routine visits for the duration of the study will be included in the post-approval study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Narinder S Shargill, PhD | Asthmatx, Inc. | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19815809 | Background | Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Duhamel DR, McEvoy C, Barbers R, Ten Hacken NH, Wechsler ME, Holmes M, Phillips MJ, Erzurum S, Lunn W, Israel E, Jarjour N, Kraft M, Shargill NS, Quiring J, Berry SM, Cox G; AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010 Jan 15;181(2):116-24. doi: 10.1164/rccm.200903-0354OC. Epub 2009 Oct 8. | |
| 23998657 |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Alair Group | Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02) Bronchial Thermoplasty with the Alair System: Bronchial Thermoplasty with the Alair System |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
AIR2 Extension Subjects Completing Follow-up at Year 1
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Alair Group | Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02, NCT00231114). |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Severe Exacerbations | The primary endpoint will be the proportion of subjects experiencing severe exacerbations during the first year after the Alair treatment compared to subsequent 12-month periods out to 5 years. This objective will be met if the upper 95% confidence limit of the difference in proportions (i.e., the subsequent 12-month proportion minus the first 12-month proportion) is less than 20%. Severe exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02). | Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up. | Posted | Number | 95% Confidence Interval | Percentage subjects severe exacerbations | 12 month periods out to 5 Years |
|
12 months out to 5 years
In previous outcome analysis and in the participant flow, the denominator was based on the number of subjects that completed the corresponding annual visit. For Adverse Events the denominator was based on all the subjects that entered that period regardless of whether they completed the annual visit or not for that period.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Year 1 | Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02). Year 1 is defined as 365 days from the treatment period (6 weeks after the last bronchoscopy). All subjects were considered in the analysis regardless of whether they have completed the Year 1 annual visit or not. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Angina pectoris | Cardiac disorders | Non-respiratory |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Asthma | Respiratory, thoracic and mediastinal disorders | Respiratory |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Narinder Shargill | Boston Scientific | 408-635-3907 | Narinder.Shargill@bsci.com |
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000074060 | Bronchial Thermoplasty |
| ID | Term |
|---|---|
| D017115 | Catheter Ablation |
| D000078703 | Radiofrequency Ablation |
| D000078702 | Radiofrequency Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
| 12 Month periods out to 5 years |
| Respiratory Adverse Events | Number of respiratory adverse events per subject per year. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the "Respiratory System" that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol. | 12 Month periods out to 5 years |
| Respiratory Adverse Events | Proportion of subjects experiencing one or more respiratory adverse event in each of the years 1 through 5 following the Alair treatment. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the "Respiratory System" that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol. | 12 Month periods out to 5 years |
| Emergency Room Visits for Respiratory Symptoms | Proportion of Subjects with Emergency Room Visits for Respiratory Symptoms | 12 Month periods out to 5 years |
| Emergency Room (ER) Visits for Respiratory Symptoms | Number of Emergency Room Visits for Respiratory Symptoms per subject per year. | 12 Month periods out to 5 years |
| Hospitalizations for Respiratory Symptoms | Proportion of subjects with hospitalizations for respiratory symptoms. | 12 Month periods out to 5 Years |
| Hospitalizations for Respiratory Symptoms | Number of Hospitalizations for Respiratory Symptoms per subject per year. | 12 Month periods out to 5 years |
| Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) | Pre-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5. | 12 Month periods out to 5 years |
| Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) | Post-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5. | 12 Month periods out to 5 years |
| Result |
| Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Hales JB, McEvoy C, Slebos DJ, Holmes M, Phillips MJ, Erzurum SC, Hanania NA, Sumino K, Kraft M, Cox G, Sterman DH, Hogarth K, Kline JN, Mansur AH, Louie BE, Leeds WM, Barbers RG, Austin JH, Shargill NS, Quiring J, Armstrong B, Castro M; Asthma Intervention Research 2 Trial Study Group. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013 Dec;132(6):1295-302. doi: 10.1016/j.jaci.2013.08.009. Epub 2013 Aug 30. |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Height (cm) | Mean | Standard Deviation | cm |
|
| Weight (kg) | Mean | Standard Deviation | kg |
|
| ICS Dose (Inhaled Corticosteroid dose) | Mean | Standard Deviation | mcg/day (micrograms/day) |
|
| LABA Dose (Long-acting Beta Agonists) | Mean | Standard Deviation | mcg/day |
|
| OCS Dose (Oral corticosteroids) | This measure includes only 7 participants using OCS at baseline. | Mean | Standard Deviation | mg/day |
|
| Asthma Quality of Life Questionnaire (AQLQ) Score | There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains. | Mean | Standard Deviation | Scores on a scale |
|
| Pre-Bronchodilator FEV1 (Forced Expiratory Volume in 1 second) | Mean | Standard Deviation | % predicted |
|
| Post-Bronchodilator FEV1 (Forced Expiratory Volume in 1 second) | Mean | Standard Deviation | % predicted |
|
| amPEF (Peak Expiratory Flow) | Mean | Standard Deviation | L/min (liters per minute) |
|
| OG000 | Alair Group | Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114). |
|
|
| Secondary | Severe Exacerbations | Number of severe exacerbations per subject per year. Severe exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02). | Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up. | Posted | Number | 95% Confidence Interval | Number of events/Number of subjects/Year | 12 Month periods out to 5 years |
|
|
|
| Secondary | Respiratory Adverse Events | Number of respiratory adverse events per subject per year. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the "Respiratory System" that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol. | Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up. | Posted | Number | 95% Confidence Interval | Number of events/number of subject/Year | 12 Month periods out to 5 years |
|
|
|
| Secondary | Respiratory Adverse Events | Proportion of subjects experiencing one or more respiratory adverse event in each of the years 1 through 5 following the Alair treatment. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the "Respiratory System" that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol. | Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up. | Posted | Number | 95% Confidence Interval | Percentage subjects with respiratory AE | 12 Month periods out to 5 years |
|
|
|
| Secondary | Emergency Room Visits for Respiratory Symptoms | Proportion of Subjects with Emergency Room Visits for Respiratory Symptoms | Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up. | Posted | Number | 95% Confidence Interval | Percentage subjects ER respir. symptoms | 12 Month periods out to 5 years |
|
|
|
| Secondary | Emergency Room (ER) Visits for Respiratory Symptoms | Number of Emergency Room Visits for Respiratory Symptoms per subject per year. | Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up. | Posted | Number | 95% Confidence Interval | Number of events/subject/year | 12 Month periods out to 5 years |
|
|
|
| Secondary | Hospitalizations for Respiratory Symptoms | Proportion of subjects with hospitalizations for respiratory symptoms. | Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up. | Posted | Number | 95% Confidence Interval | Percentage of subjects hospitalized | 12 Month periods out to 5 Years |
|
|
|
| Secondary | Hospitalizations for Respiratory Symptoms | Number of Hospitalizations for Respiratory Symptoms per subject per year. | Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up. | Posted | Number | 95% Confidence Interval | Number of events/subjects/year | 12 Month periods out to 5 years |
|
|
|
| Secondary | Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) | Pre-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5. | Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up. | Posted | Mean | Standard Deviation | Percentage of change from Baseline | 12 Month periods out to 5 years |
|
|
|
| Secondary | Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) | Post-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5. | Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up. | Posted | Mean | Standard Deviation | Percentage of change from Baseline | 12 Month periods out to 5 years |
|
|
|
| 5 |
| 187 |
| 112 |
| 187 |
| EG001 | Year 2 | Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02). Year 2 is defined as 366 to 730 days after the treatment period. All subjects were considered in the analysis regardless of whether they have completed the Year 2 annual visit or not. | 8 | 168 | 89 | 168 |
| EG002 | Year 3 | Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02). Year 3 is defined as 731 to 1095 days after the treatment period. All subjects were considered in the analysis regardless of whether they have completed the Year 3 annual visit or not. | 10 | 163 | 81 | 163 |
| EG003 | Year 4 | Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02). Year 4 is defined as 1096 to 1460 days after the treatment period. All subjects were considered in the analysis regardless of whether they have completed the Year 4 annual visit or not. | 9 | 163 | 77 | 163 |
| EG004 | Year 5 | Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02). Year 5 is defined as 1461 days to 1826 days after the treatment period. All subjects were considered in the analysis regardless of whether they have completed the Year 5 annual visit or not. | 3 | 162 | 61 | 162 |
| Angina unstable | Cardiac disorders | Non-respiratory |
|
| Myocardial infarction | Cardiac disorders | Non-respiratory |
|
| Supraventricular tachycardia | Cardiac disorders | Non-respiratory |
|
| Addison's disease | Endocrine disorders | Non-respiratory |
|
| Abdominal pain | Gastrointestinal disorders | Non-respiratory |
|
| Anorectal disorder | Gastrointestinal disorders | Non-respiratory |
|
| Gastritis | Gastrointestinal disorders | Non-respiratory |
|
| Haemorrhoids | Gastrointestinal disorders | Non-respiratory |
|
| Umbilical hernia | Gastrointestinal disorders | Non-respiratory |
|
| Pyrexia | General disorders | Non-respiratory |
|
| Cholecystitis acute | Hepatobiliary disorders | Non-respiratory |
|
| Cholelithiasis | Hepatobiliary disorders | Non-respiratory |
|
| Abscess limb | Infections and infestations | Non-respiratory |
|
| Appendicitis | Infections and infestations | Non-respiratory |
|
| Cellulitis | Infections and infestations | Non-respiratory |
|
| Infective tenosynovitis | Infections and infestations | Non-respiratory |
|
| Osteomyelitis | Infections and infestations | Non-respiratory |
|
| Perianal abscess | Infections and infestations | Non-respiratory |
|
| Pyelonephritis | Infections and infestations | Non-respiratory |
|
| Viral labyrinthitis | Infections and infestations | Non-respiratory |
|
| Foot fracture | Injury, poisoning and procedural complications | Non-respiratory |
|
| Head injury | Injury, poisoning and procedural complications | Non-respiratory |
|
| Incisional hernia | Injury, poisoning and procedural complications | Non-respiratory |
|
| Injury | Injury, poisoning and procedural complications | Non-respiratory |
|
| Road traffic accident | Injury, poisoning and procedural complications | Non-respiratory |
|
| Traumatic brain injury | Injury, poisoning and procedural complications | Non-respiratory |
|
| Obesity | Metabolism and nutrition disorders | Non-respiratory |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | Non-respiratory |
|
| Chondrocalcinosis pyrophosphate | Musculoskeletal and connective tissue disorders | Non-respiratory |
|
| Musculoskeletal chest pain | Musculoskeletal and connective tissue disorders | Non-respiratory |
|
| Osteonecrosis | Musculoskeletal and connective tissue disorders | Non-respiratory |
|
| Acute myeloid leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-respiratory |
|
| Breast cancer in situ | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-respiratory |
|
| Chronic myeloid leukaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-respiratory |
|
| Pituitary tumour | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-respiratory |
|
| Uterine leiomyoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-respiratory |
|
| Headache | Nervous system disorders | Non-respiratory |
|
| Paraesthesia | Nervous system disorders | Non-respiratory |
|
| Sciatica | Nervous system disorders | Non-respiratory |
|
| Abortion spontaneous | Pregnancy, puerperium and perinatal conditions | Non-respiratory |
|
| Nephrolithiasis | Renal and urinary disorders | Non-respiratory |
|
| Asthma | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
| Bronchitis | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
| Chest pain | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
| Cough | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
| Lobar pneumonia | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
| Lower respiratory tract infection | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
| Pneumonia | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
| Sinusitis | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
| Knee arthroplasty | Surgical and medical procedures | Non-respiratory |
|
| Arteriosclerosis | Vascular disorders | Non-respiratory |
|
| Bronchitis | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
| Lower respiratory tract infection | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
| Nasopharyngitis | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
| Sinusitis | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
| Upper respiratory tract infection | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
| Viral upper respiratory tract infection | Respiratory, thoracic and mediastinal disorders | Respiratory |
|
Not provided
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D055011 |
| Ablation Techniques |
| D013514 | Surgical Procedures, Operative |
| Title | Measurements |
|---|---|
|
| Year 4 |
|
| Year 5 |
|
| Title | Measurements |
|---|---|
|
| Year 4 |
|
| Year 5 |
|
| Title | Measurements |
|---|---|
|
| Year 4 |
|
| Year 5 |
|
| Title | Measurements |
|---|---|
|
| Year 4 |
|
| Year 5 |
|
| Title | Measurements |
|---|---|
|
| Year 4 |
|
| Year 5 |
|
| Title | Measurements |
|---|---|
|
| Year 4 |
|
| Year 5 |
|
| Title | Measurements |
|---|---|
|
| Year 4 |
|
| Year 5 |
|
| Title | Measurements |
|---|---|
|
| Year 4 |
|
| Year 5 |
|
| Title | Measurements |
|---|---|
|
| Year 4 |
|
| Year 5 |
|